• Genetically engineered temperature-sensitive class I HLA mutants are provided which can be used in a method to obtain peptides which are bound to MHC class I molecules on the surfaces of cells that are transfected with the mutant genes. (google.com)
  • The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. (uniprot.org)
  • The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. (uniprot.org)
  • Because invasive bladder cancers are frequently reported to express MAGE, we explored the possibility of establishing a new immunotherapeutic modality against advanced bladder cancer using autologous DCs pulsed with one of the MAGE-3 epitope peptides (IMPKAGLLI), which is synthesized to bind specifically to HLA-A24. (aacrjournals.org)
  • In this previous report, five peptides of nine amino acids were found to contain the binding motif for HLA-A24 in the known sequence of MAGE-3. (aacrjournals.org)
  • These peptides were synthesized and tested for their binding ability to purified HLA-A24 molecules. (aacrjournals.org)
  • Significant T cell responses were detected against 8 of 45 peptides with an HLA class I affinity of K(D) less than or equal to 5 nM, whereas no T cell responses were detected against 60 peptides with an HLA affinity of K(D) more than 5 nM. (dtu.dk)
  • DCs are the most potent professional antigen-presenting cells for inducing anticancer immunity both in vitro and in vivo . (aacrjournals.org)
  • Professional antigen-presenting cells activate naive T cells through MHC-II complex/TCR and B7(CD80/86)/CD28 co-stimulatory binding. (biomedcentral.com)
  • There was no correlation between measured alloresponses and mRNA expression of the mismatched HLA-C alleles. (frontiersin.org)
  • We also identified HLA-C*02:02 and HLA-C*06:02 as mismatched alleles with lower immunogenicity, and HLA-C*14:02 as a more immunogenic MM. A difference of at least 10 aa residues known to impact peptide/T cell receptor (TCR) binding and a bystander HLA-DPB1 incompatibility had a significant impact on CTL alloreactivity ( p = 0.021). (frontiersin.org)
  • In conclusion, mismatched HLA-C alleles differing by 10 or more aas in the peptide/TCR-binding region, when occurring together with HLA-DPB1 incompatibilities, should be considered as high-risk MMs in unrelated HSCT. (frontiersin.org)
  • Donor search algorithms are now complicated by the growing number of new HLA alleles, in particular those that differ outside the peptide-binding site of the HLA molecules. (uzh.ch)
  • Hundreds of HLA-B alleles have been described. (nih.gov)
  • HLA-B alleles are associated with dermatitis herpetiformis in Chinese population. (nih.gov)
  • HLA-B13:02, HLA-B38:02, HLA-B44:03, and HLA-B56:01 alleles were significantly increased in autistic subjects. (nih.gov)
  • HLA-B18:02 and HLA-B46:12 alleles were negatively associated with autism when compared to normal controls. (nih.gov)
  • The HLA Alleles B*0801 and DRB1*0301 Are Associated with Dermatitis Herpetiformis in a Chinese Population. (nih.gov)
  • Significant Association of HLA-B Alleles and Genotypes in Thai Children with Autism Spectrum Disorders: A Case-Control Study. (nih.gov)
  • TCRs can exhibit high or low degrees of HLA-restricted cross-reactivity and alloreact against one or a combination of HLA alleles. (frontiersin.org)
  • HLA-DR53 specificity -encoded by HLA-DRB4 - is exclusively found in association with haplotypes encoding the DR4, DR7 and DR9 broad specificities (i.e., all DRB1*04, *07, *09 alleles). (dorak.info)
  • The latest list of officially recognized HLA-DRB alleles can be found at the ANRC site . (dorak.info)
  • The distribution of MHC class I alleles in this RESPI population proved similar to CVID, with almost half of the patients inheriting HLA-B44. (beds.ac.uk)
  • A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. (ox.ac.uk)
  • T cell-mediated alloresponses were correlated with genetic markers such as HLA-C mRNA expression and the number of amino acid (aa) MMs in the α1/α2 domains (peptide-binding region). (frontiersin.org)
  • This is the first demonstration that a single HLA-B mismatch involving a residue outside the peptide-binding site is not recognized in an in vitro functional assay and may probably be considered as a permissive incompatibility in vivo. (uzh.ch)
  • More generally, minor histocomplatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. (uniprot.org)
  • (14) reported the successful induction of antitumor CTLs with a MAGE-3-encoded synthetic peptide presented by HLA-A24. (aacrjournals.org)
  • Using this particular model, we explored the possibility of inducing a significant MAGE-specific CTL response by the in vitro stimulation of PBMCs with autologous DCs pulsed with the MAGE-3 synthetic epitope peptide, IMPKAGLLI, which binds to HLA-A24 molecules with a very high affinity. (aacrjournals.org)
  • Minimal tolerance to a tumor antigen encoded by a cancer-germline gene. (nih.gov)
  • Ternary structures of TRBV6-1, TRBV6-4, and TRBV20(+) MAIT TCRs in complex with MR1 bound to a potent riboflavin-based antigen (Ag) showed how variations in TRBV gene usage exclusively impacted on MR1 contacts within a consensus MAIT TCR-MR1 footprint. (jove.com)
  • TCR gene therapy allows for the mass redirection of T-cells against a defined antigen while high affinity TCR engineering allows for the creation of a new class of soluble drugs. (frontiersin.org)
  • HLA-DR53 is not expressed on the HLA-B57DR7Dw11DQ9 (DQA1*02:01, DQB1*03:03) haplotype (as in the cell line DBB (IHW 9052) representing the conserved extended haplotype (CEH) 57.1) due to a base substitution at the 3' end of the first intron of the gene 9;10 . (dorak.info)
  • In fact, the null allele of the HLA-DRB4 gene ( DRB4*0103102N ) is transcribed, but it is an aberrant protein due to the lack of splicing out of the first exon 11 . (dorak.info)
  • Furthermore, there was a trend toward higher plasma levels of soluble HLA-E in KD patients with the CT and TT genotypes of the HLA-E gene polymorphism. (docme.ru)
  • Our results suggest that the HLA-E gene polymorphism may play a role in the pathogenesis of KD. (docme.ru)
  • Incompatibilities at HLA classes I and II loci are associated with an increased risk of graft-versus-host disease (GVHD) and mortality, although no consensus exists yet on the relative importance of specific allele disparities on clinical outcome. (uzh.ch)
  • The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients. (nih.gov)
  • Of these, HLA*B44 was present in almost half of the patients and was thus the most common susceptibility allele. (beds.ac.uk)
  • each allele is defined as a single antigen assigned by serological typing criteria, e.g. (kidneydiseaseauthority.com)
  • An individual's T cells recognize and are activated by protein antigens only if a fragment of the antigen is properly presented on the surface of a target cell. (google.com)
  • To get better insight into presumably permissive HLA-C MMs, we have developed a one-way in vitro mixed lymphocyte reaction (MLR) assay allowing to quantify activated CD56 − CD137 + CD8 + lymphocytes in HLA-C incompatible combinations. (frontiersin.org)
  • Recently, a few retrospective clinical studies have reported some variability in the immunogenicity of HLA-C incompatibilities. (frontiersin.org)
  • The results show that natural polymorphisms within HIV-1 Nef modulate its interaction with natural polymorphisms in the HLA cytoplasmic tails, thereby affecting the efficiency of HLA downregulation and consequent recognition by HIV-specific T cells. (nih.gov)
  • HLA-B44 increases recurrent sinopulmonary infections. (wikipedia.org)
  • HLA *B44 was also found to be over-represented among patients who presented to our clinic with adult-onset recurrent sinopulmonary infections (RESPI) and normal serum immunoglobulin levels, a cohort that included first and second degree relatives of patients with CVID. (beds.ac.uk)
  • For the alignment of DRB4 allelic sequences, see the IMGT/HLA Sequence Database alignment page . (dorak.info)
  • 5 6 Especially in uveal melanoma there is evidence that the downregulation of HLA-A and -B antigens correlates with a favorable patient outcome, 7 8 which is completely different from the situation known to exist with other tumors. (arvojournals.org)
  • Relative Resistance of HLA-B to Downregulation by Naturally Occurring HIV-1 Nef Sequences. (nih.gov)
  • We identified 63 CVID patients irrespective of HLA status and 13 RESPI patients who had inherited HLA*B44. (beds.ac.uk)
  • Antibodies to HLA-B44 were noted in the second unit of transfused blood, and the corresponding antigen was expressed on the transplanted (affected) lung but not in the native (uninvolved) lung. (infectiousdiseaseadvisor.com)
  • In addition, while HLA antibodies are commonly identified in female donors, only a very small percent of these donors are implicated in TRALI. (infectiousdiseaseadvisor.com)
  • Furthermore, transfusion of blood products from donors with known HLA antibodies to recipients with corresponding antigens causes lung injury in only some of the recipients. (infectiousdiseaseadvisor.com)
  • Original Article from The New England Journal of Medicine - Antibodies against MICA Antigens and Kidney-Transplant Rejection. (kidneydiseaseauthority.com)
  • Hyperacute rejection, an extremely rare occurrence, develops within seconds of implantation as a result of high levels of antibodies against antigens on the endothelium of glomeruli and microvasculature of. (kidneydiseaseauthority.com)
  • The role of HLA-specific antibodies in kidney transplant rejection: published studies and local. (kidneydiseaseauthority.com)
  • The HLA-DRB4 promoter polymorphism is associated with differential expression of this locus 4 and this occurs at the level of mRNA production 3 . (dorak.info)
  • Understanding the obstacle of incompatibility at residue 156 within HLA-B*35 subtypes. (nih.gov)
  • performed a pionnering clinical trial demonstrating the rapid generation of T cell immunity against recall antigens and Keyhole Limpet Hemocyanin in normal volunteers [ 4 ] and Schüler-Thurner et al. (biomedcentral.com)
  • An HLA-C amino-acid variant in addition to HLA-B*27 confers risk for ankylosing spondylitis in the Korean population. (nih.gov)
  • A search for genetic markers of HLA-C expression led to the description of two relevant polymorphisms. (frontiersin.org)